Skip to content

Study · Systematic review · n = 13,378 · 2025

6 results

Effect of Tirzepatide on Heart Failure in Type 2 Diabetes Mellitus and Obesity: A Systematic Review and Meta-Analysis.

He YM, Zeng C, Zhang YF, Wu Q, Zhou XY, Yan PJ, Xu Y, Guo M, Teng FY

Diabetes/metabolism research and reviews1 Oct 2025Cited by 1 (Europe PMC)

PMID41100405 (opens in a new tab)DOI10.1002/dmrr.70097 (opens in a new tab)PepBankPUB-41100405
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes or obesity, a meta-analysis of randomized trials found a neutral effect of tirzepatide on overall heart failure risk versus placebo or other glucose-lowering drugs.

    In plain wordsAcross trials, tirzepatide did not clearly raise or lower the risk of heart failure compared with placebo or other glucose-lowering drugs.

    Peptide
    Tirzepatide
    Outcome
    No significant changeOverall heart failure risk
    Study

    n = 13,378

    Comparator
    Placebo or other active glucose-lowering drugs
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.63 ratio
    heart failure, overall
    Absolute risk reduction
    0.17%
    heart failure, overall
    Number needed to treat
    588 patients
    heart failure, overall

    Source sentences

    Summary
    tirzepatide had a neutral effect on the overall risk for heart failure (risk ratio [RR] 0.63 [95% confidence interval (CI) 0.35-1.13]), but the effect was neither statistically nor clinically meaningful (absolute risk reduction [ARR] 0.17%, number needed to treat [NNT] 588
    1 context sentence
    Summary · context
    Eleven randomized controlled trials (RCTs) (funded by Eli Lilly and Co., Indianapolis, IN, USA) comprising 13,378 participants were included.
  2. 02HumanSystematic reviewSafety outcome

    In the subgroup aged 58 years or younger, tirzepatide was linked to a lower heart failure risk than comparators in a meta-analysis of randomized trials.

    In plain wordsIn people aged 58 or younger, trials linked tirzepatide to a lower heart failure risk than comparators. This was a subgroup result.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHeart failure risk in patients aged 58 years or younger
    Study

    n: not reported in source

    Comparator
    Placebo or other active glucose-lowering drugs
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.4 ratio
    age 58 years or younger

    Source sentences

    Summary
    Subgroup analysis revealed different pooled estimates for heart failure outcomes in the ≤ 58 years of age subgroup (RR 0.40 [95% CI 0.17-0.96]) compared with the > 58 years' subgroup (RR 0.86 [95% CI 0.39-1.90]) (p for interaction = 0.201).
    1 context sentence
    Summary · context
    Eleven randomized controlled trials (RCTs) (funded by Eli Lilly and Co., Indianapolis, IN, USA) comprising 13,378 participants were included.
  3. 03HumanSystematic reviewSafety outcome

    In the subgroup older than 58 years, tirzepatide showed no significant change in heart failure risk versus comparators in a meta-analysis of randomized trials.

    In plain wordsIn people older than 58, trials found no clear change in heart failure risk with tirzepatide compared with comparators.

    Peptide
    Tirzepatide
    Outcome
    No significant changeHeart failure risk in patients older than 58 years
    Study

    n: not reported in source

    Comparator
    Placebo or other active glucose-lowering drugs
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.86 ratio
    age over 58 years

    Source sentences

    Summary
    Subgroup analysis revealed different pooled estimates for heart failure outcomes in the ≤ 58 years of age subgroup (RR 0.40 [95% CI 0.17-0.96]) compared with the > 58 years' subgroup (RR 0.86 [95% CI 0.39-1.90]) (p for interaction = 0.201).
    1 context sentence
    Summary · context
    Eleven randomized controlled trials (RCTs) (funded by Eli Lilly and Co., Indianapolis, IN, USA) comprising 13,378 participants were included.
  4. 04HumanSystematic reviewSafety outcome

    In the subgroup that used tirzepatide alone, tirzepatide was linked to a lower heart failure risk than comparators in a meta-analysis of randomized trials.

    In plain wordsIn trials where tirzepatide was used alone, it was linked to a lower heart failure risk than comparators.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHeart failure risk with tirzepatide monotherapy
    Study

    n: not reported in source

    Comparator
    Placebo or other active glucose-lowering drugs
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Risk ratio
    0.43 ratio
    tirzepatide alone

    Source sentences

    Summary
    Additionally, subgroup analysis comparing tirzepatide alone with tirzepatide in combination with other agents revealed different pooled estimates (p = 0.661; I2 = 0.0%), with an RR 0.43 (95% CI 0.20-0.88) and 2.25 (95% CI 0.51-9.87), respectively (p for interaction = 0.05).
    1 context sentence
    Summary · context
    Eleven randomized controlled trials (RCTs) (funded by Eli Lilly and Co., Indianapolis, IN, USA) comprising 13,378 participants were included.
  5. 05HumanSystematic reviewSafety outcome

    Subgroup analyses by tirzepatide dose, baseline body weight, BMI, glucose, glycated haemoglobin, disease type and intervention time showed no association between tirzepatide and heart failure risk.

    In plain wordsAcross dose, body weight, blood sugar and treatment time subgroups, trials found no link between tirzepatide and heart failure risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeHeart failure risk by tirzepatide dose, baseline characteristics and intervention time
    Study

    n: not reported in source

    Comparator
    Placebo or other active glucose-lowering drugs
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Subgroup analyses stratified according to different doses of tirzepatide, baseline body weight, body mass index, fasting plasma glucose, glycated haemoglobin, T2DM, obesity, or overweight, and intervention time indicated no association between tirzepatide use and the risk for heart failure.
    1 context sentence
    Summary · context
    Eleven randomized controlled trials (RCTs) (funded by Eli Lilly and Co., Indianapolis, IN, USA) comprising 13,378 participants were included.

Studies that did not test the peptide alone1

In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Tirzepatide.

  1. 06HumanNot a test of Tirzepatide aloneSystematic reviewSafety outcome

    In the subgroup of trials that gave tirzepatide in combination with other agents, the regimen showed no significant change in heart failure risk versus comparators.

    In plain wordsIn trials where tirzepatide was given with other drugs, the regimen showed no clear change in heart failure risk.

    Peptide
    Tirzepatide
    Outcome
    No significant changeHeart failure risk with tirzepatide combined with other agents
    Study

    n: not reported in source

    Comparator
    Placebo or other active glucose-lowering drugs
    Outcome group
    Cardiovascular events · Cardiovascular

    Measurements

    Risk ratio
    2.25 ratio
    tirzepatide combined with other agents

    Source sentences

    Summary
    Additionally, subgroup analysis comparing tirzepatide alone with tirzepatide in combination with other agents revealed different pooled estimates (p = 0.661; I2 = 0.0%), with an RR 0.43 (95% CI 0.20-0.88) and 2.25 (95% CI 0.51-9.87), respectively (p for interaction = 0.05).
    1 context sentence
    Summary · context
    Eleven randomized controlled trials (RCTs) (funded by Eli Lilly and Co., Indianapolis, IN, USA) comprising 13,378 participants were included.

    In this study, Tirzepatide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Tirzepatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.